SLC6A6 and ovarian cancer: TSA reduces cell viability in cisplatin-resistant human ovarian cancer cells by inhibiting the volume-sensitive organic anion channel (VSOAC) via the induction of taurine transporter (TauT) activity and inducing autophagic cell death [295].